OncoMatch/Clinical Trials/NCT06196788
Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
Is NCT06196788 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Gemcitabine and Nab paclitaxel for pancreatic cancer.
Treatment: Gemcitabine · Nab paclitaxel — The purpose of this study is to evaluate the efficacy of gemcitabine and nab-paclitaxel venous injection plus transcatheter arterial infusion to Patients with Advanced Pancreatic Cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: anti-tumor chemotherapy
Patients who have received anti-tumor chemotherapy, radiotherapy, or other treatments.
Cannot have received: radiotherapy
Patients who have received anti-tumor chemotherapy, radiotherapy, or other treatments.
Cannot have received: other major anti-cancer treatments
Primary pancreatic cancer without major anti-cancer treatments.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06196788 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages